Clinical trials: Mammary Cancer
Invasive Breast Cancer, Ductal Carcinoma in Situ of the Breast
Axillary Reverse Mapping (ARM) Technique
The purpose of this pilot study is to compare a new surgical technique (axillary reverse mapping) to standard axillary surgery in patients diagnosed with invasive or in situ breast cancer.
- Trial name
- ARM (NCT03109522)
- Testing
- axillary reverse mapping (ARM), Standard axillary surgery (SLNB or ALND)
- Where
- 2 sites in Canada
- Volunteers
- 130 people
- Sponsor
- McMaster University
Breast Cancer, Insomnia
Treatment of Insomnia in Patients With Breast Cancer
Insomnia, defined as difficulty falling asleep, staying asleep, or waking up too early at least three times a week for at least 3 months, (American Psychiatric Association 2013) is a common disorder both in the general population…
- Trial name
- NCT06061666
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer.
- Trial name
- NCT03568422
- Testing
- CFI-402257, Paclitaxel
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Canadian Cancer Trials Group
Breast Carcinoma
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy.
- Trial name
- NCT05557877
- Testing
- Biospecimen Collection, Low-Dose Aspirin, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Carcinoma, Ductal, Breast
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast cancer.
- Trial name
- NCT01891357
- Testing
- Biopsy before and after three weeks of study treatment, paclitaxel, lapatinib
- Where
- 10 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer, Fatigue
Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve fatigue and certain thinking skills in women with breast cancer receiving chemotherapy.
- Trial name
- NCT03487601
- Testing
- transcranial direct current stimulation
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Cancer
Evaluation of Sexual Quality of Life for Breast Cancer
Breast cancer is the most common cancer in women worldwide. Hormonal therapy is one of the major treatments for hormone receptor positive breast tumors. It is prescribed to 70% of breast cancer patients.
- Conditions
- Breast Cancer, Cancer, Quality of Life
- Trial name
- CUPIDON2 (NCT04200001)
- Testing
- Quality of life
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer
Breast cancer is the most frequent malignancy in women. Standard therapy for early-stage breast cancer is breast conserving surgery (BCS) followed by adjuvant whole breast irradiation (WBI), which usually requires a treatment…
- Trial name
- COSMOPOLITAN (NCT03838419)
- Testing
- intraoperative radiotherapy, whole breast irradiation
- Where
- Germany
- Volunteers
- 101 people
- Sponsor
- University Hospital Heidelberg
HR+/HER2- Breast Cancer
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole…
- Trial name
- KANDELA-302 (NCT07492641)
- Testing
- BGB-43395, Letrozole, Abemaciclib
- Where
- 241 sites in United States, Australia and 14 more
- Volunteers
- 1,056 people
- Sponsor
- BeOne Medicines
Breast Neoplasm
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
To compare disease-free survival (DFS) rate of adjuvant chemotherapy epirubicin-cyclophosphamide followed by weekly paclitaxel or docetaxel (EC-T), or weekly paclitaxel or docetaxel-carboplatin (EC-TCb) in triple-negative breast…
- Trial name
- TCTN (NCT02455141)
- Testing
- Epirubicin plus Cyclophosphamide, Taxanes, Taxanes plus Carboplatin
- Where
- 27 sites in China
- Volunteers
- 786 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Paravertebral Block (PVC) Versus Pectoral Nerve Block (PEC)
The purpose of this study is to compare two standard methods of pain control management used at Spectrum Health for patients undergoing breast surgery.
- Trial name
- NCT03152929
- Testing
- Paravertebral Block, Pectoral Nerve Block
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Corewell Health West
Breast Carcinoma
ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers
This study is being done to determine if a clinically available MRI sequence called ZTE imaging better visualizes breast biopsy markers made of bone cement compared to the currently used breast biopsy markers made of metal.
- Trial name
- NCT06873802
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer
The purpose of this research study is to learn about the effects that standard of care endocrine therapies have on the immune system's response to cancer by looking at the number and types of immune cells present and how they…
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy
- Trial name
- NCT03719495
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Duke University
Breast Cancer
Cosmetic and Functional Outcomes After Breast Conserving Surgery
The initial aesthetic and functional conditions are recorded with the help of the Breast Cancer Treatment Outcome Scale (BCTOS),an international validated questionnaire, and the Breast Cancer Conservative Treatment - cosmetic…
- Trial name
- NCT01496001
- Testing
- Lumpectomy, axillary block dissection, breast conserving surgery, Radiotherapy
- Where
- Hungary
- Volunteers
- 300 people
- Sponsor
- National Institute of Oncology, Hungary
Breast Cancer
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Patients with HER-2 positive breast cancer who have poor outcomes after endocrinotherapy and standard chemotherapy can be significantly improved by the use of anti-HER-2 monoclonal antibody trastuzumab.
- Trial name
- NCT04973319
- Testing
- Pyrotinib, Trastuzumab
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shengjing Hospital
Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
This is an open-label, multi-center, dose-finding study of tivozanib administered in combination with capecitabine. During the dose-escalation portion, sequential cohorts of subjects with advanced solid tumors will be enrolled in…
- Trial name
- NCT01306630
- Testing
- tivozanib (AV-951) and capecitabine (Xeloda®)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but…
- Trial name
- NCT06440967
- Testing
- Fezolinetant, Tamoxifen, Aromatase inhibitor
- Where
- 110 sites in Canada, Czechia and 9 more
- Volunteers
- 982 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Neoplasm, Colorectal Neoplasm
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer.
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider
- Trial name
- NCT03141437
- Testing
- Best Practice, Educational Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor…
- Trial name
- NCT05950945
- Testing
- Trastuzumab Deruxtecan
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo
Breast Cancer
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients.
- Trial name
- IMPACt (NCT02670577)
- Where
- 17 sites in United States
- Volunteers
- 481 people
- Sponsor
- Agendia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.